Aeon Biopharma Business Update
AEON Biopharma received official minutes from a Type 2b meeting with the FDA regarding the biosimilar development pathway for ABP-450, a proposed biosimilar to BOTOX. The FDA agreed in principle with a proposed two-stage pharmacodynamic study design, and the company plans to submit an IND for this study in Q4 2026 with initiation expected in Q1 2027. The feedback supports a potentially streamlined development path that may leverage existing comparative human evidence to avoid or narrow the scope of standalone comparative efficacy studies.
- Counterparty
- FDA